MHRA-100545-PIP01-22

Key Facts

Active Substance
Active Substance:
  • Lutetium (177Lu) edotreotide
Invented Name
Not yet available
PIP Number MHRA-100545-PIP01-22
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Lutetium (177Lu) edotreotide.pdf
Published Date 25/05/2023